ALIROCUMAB REDUCES MAJOR CARDIOVASCULAR EVENTS IN INDIVIDUALS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A POST-HOC ANALYSIS OF ODYSSEY LONG TERM
2017
Background: Individuals with elevated low density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) are at increased risk for recurrent events. We present a post-hoc analysis of the efficacy and safety of alirocumab (ALI) vs. placebo (PL) among individuals with ASCVD
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI